Sign in
Taking people in South KoreaPhase 2/3

Compares zanzalintinib with everolimus in people with advanced neuroendocrine tumors

Tests zanzalintinib against everolimus in adults with previously treated neuroendocrine tumors.

Key facts

Who runs it
Exelixis
Where
Seoul, South KoreaSee the 5 sitesAlso in 17 other countries, 130 sites
Registry title
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Status
Recruiting
Phase
Phase 2/3
People taking part
440 people, planned
Started
21 Jul 2025
Expected to end
30 Jun 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Zanzalintinib
  • Everolimus
Record updated
30 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with well-differentiated neuroendocrine tumors that have spread or cannot be removed by surgery. The tumors must have grown despite earlier treatment.

Age
18 years or older
Sex
All sexes can join
Disease stage
Well-differentiated Grade 1, 2 or 3 neuroendocrine tumors, from the pancreas or from outside the pancreas. Locally advanced and cannot be removed by surgery, or spread to other parts of the body. Imaging must show the disease grew within the last 12 months, and the disease must be measurable.
Earlier treatment
Earlier lines of treatment are allowed, depending on where the tumor is and whether it makes hormones. People who had a VEGFR-targeting tyrosine kinase inhibitor or an mTOR inhibitor cannot join.
Biomarker or test result
Archival tumor tissue is needed if available. If not, a fresh biopsy may be used if it can be done safely.

Main reasons for not taking part

  • Neuroendocrine carcinoma (including small cell lung cancer), medullary thyroid cancer, pheochromocytoma, paraganglioma, Merkel cell carcinoma or mixed neuroendocrine non-neuroendocrine neoplasm
  • Earlier treatment with a VEGFR-targeting tyrosine kinase inhibitor or an mTOR inhibitor
  • Systemic chemotherapy or liver-directed or other ablative therapy within 4 weeks before randomization
  • Systemic radionuclide therapy within 6 weeks before randomization
  • Radiation therapy for bone metastases within 2 weeks, or other radiation therapy within 4 weeks before randomization

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Histologically confirmed, locally advanced/unresectable or metastatic, well-differentiated Grade 1, 2, or 3 NETs of pancreatic origin or extra-pancreatic origin
  • Allowed prior lines of therapy, based on the site of NET and functional status
  • Documented radiographic disease progression per RECIST 1.1, as assessed by the Investigator based on imaging assessments (computed tomography [CT] or magnetic resonance imaging [MRI]) within 12 months before randomization
  • Measurable disease according to RECIST 1.1 as determined by the Investigator
  • Archival tumor tissue is required, if available. If archival tumor tissue is not available, a fresh biopsy may be submitted if it can be safely and feasibly obtained. Every attempt should be made to provide tumor tissue

Who cannot take part

  • Prior treatment with a vascular endothelial growth factor receptor (VEGFR) -targeting tyrosine kinase inhibitor or a mammalian target of rapamycin (mTOR) inhibitor
  • Systemic chemotherapy and any liver-directed or other ablative therapy within 4 weeks before randomization
  • Systemic radionuclide therapy within 6 weeks before randomization
  • Radiation therapy for bone metastases within 2 weeks, any other radiation therapy, except as indicated above, within 4 weeks before randomization; Note: Other protocol defined Inclusion/Exclusion criteria may apply
  • Histologically confirmed neuroendocrine carcinomas (including small cell lung cancer), medullary thyroid cancer, pheochromocytoma, paraganglioma, Merkel cell carcinoma, and mixed neuroendocrine non-neuroendocrine neoplasm (MiNEN)

Where in South Korea

Also in 17 other countries, 130 sites

  • Asan Medical CenterSeoul, South KoreaContact: Exelixis Clinical TrialsTaking people
  • Korea University Anam HospitalSeoul, South KoreaContact: Exelixis Clinical TrialsTaking people
  • Samsung Medical CenterSeoul, South KoreaContact: Exelixis Clinical TrialsTaking people
  • Seoul National University HospitalSeoul, South KoreaContact: Exelixis Clinical TrialsTaking people
  • Severence Hospital, Yonsei University Health SystemSeoul, South KoreaContact: Exelixis Clinical TrialsTaking people

About the trial

What the trial wants to find out

The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.

The 2 groups in the trial

  • EverolimusExisting treatment, for comparison

    Participants will receive everolimus oral tablets once daily.

  • ZanzalintinibTreatment being tested

    Participants will receive zanzalintinib oral tablets once daily.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors
Plain-language title
Compares zanzalintinib with everolimus in people with advanced neuroendocrine tumorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
30 October 2026